HIGHLIGHTS
- who: Simone Kumstel and colleagues from the Rudolf-Zenker-Institute of Experimental Surgery, University Medical Center, Rostock, Germany, Core have published the research work: Targeting pancreatic cancer with combinatorial treatment of CPI-613 and inhibitors of lactate metabolism, in the Journal: PLOS ONE of 31/03/2021
- what: This study evaluated the anti-cancerous efficacy of CPI-613 in combination with galloflavin a lactate dehydrogenase inhibitor or with alpha-cyano-4hydroxycinnamic acid an inhibitor of monocarboxylate transporters. The efficacy of CPI in combination with FOLFIRINOX was already tested in a phase 1 clinical study for . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.